Shining Light on the Commercial Potential of Optogenetic Therapies

In a guest column at, the authors discuss the past and exciting future prospects of optogenetic therapies. Companies like GenSight, Nanoscope Therapeutics, and more are compared side by side in their "race" to get their optogenetic treatment FDA approved.

What this means for Usher syndrome: Recognizing the importance of past limitations with retinal treatments allows scientists to learn and create future therapies that are better.

Link to original article